ScreenerHero

TGTX TG Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · tgtherapeutics.com
52.95USD+1.46%Mkt Cap: 8.11B $P/E: 19.25

TG Therapeutics, Inc., a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationall…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap8.11B USD
Enterprise Value7.61B USD
Revenue (TTM)799.54M USD
Gross Profit515.57M USD
Net Income (TTM)447.18M USD
Revenue/Share5.61 USD
Last Price52.95 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees399
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)19.25
P/E (Forward)19.27
PEG1.61
EV/EBITDA55.74
EV/Revenue9.51
P/S9.99
P/B12.69
EPS (TTM)2.66
EPS (Forward)2.71
52W Range
26.7680% of range59.30
52W High59.30 USD
52W Low26.76 USD
Profitability
Gross Margin83.66%
Oper. Margin9.02%
EBITDA Margin17.07%
Profit Margin72.56%
ROE69.01%
ROA42.06%
Growth
Revenue Growth70.30%
Earnings Growth-70.60%
Cash Flow & Leverage
Operating CF-24.77M USD
CapEx (TTM)214.00K USD
FCF Margin7.40%
FCF Yield0.73%
Net Debt202.19M USD
Net Debt/EBITDA1.48
Balance Sheet
Debt/Equity0.39
Current Ratio4.27
Quick Ratio3.55
Book Value/Sh4.11 USD
Cash/Share3.89 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Splits
Last Split100:5625
Split DateApr 30, 2012
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)69.71 USD
Upside (mean)+31.7%
Target Range21.00 USD – 86.00 USD
21.00+31.7% to mean86.00
# Analysts7
Ownership
Shares Out.153.07M
Float135.24M
Insiders7.47%
Institutions74.60%
Short Interest
Short Ratio16.8d
Short % Float28.47%
Short % Out.19.70%
Shares Short30.15M
Short (prev mo.)30.11M
Technical
SMA 5053.59 (-1.2%)
SMA 20041.54 (+27.5%)
Beta1.80
S&P 52W Chg16.45%
Avg Vol (30d)1.88M
Avg Vol (10d)1.73M
Technical Indicators
RSI (14)44.2
MACD-0.0577
MACD Signal0.5093
MACD Hist.-0.5670
BB Upper58.51 USD
BB Middle55.33 USD
BB Lower52.14 USD
BB Width11.51%
ATR (14)2.297 USD
Vol Ratio (20d)0.84x